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Available online at www.sciencedirect.comAging is accompanied by the functional decline of cells, tissues,
and organs, as well as a striking increase in a wide range of
diseases. The reprogramming of somatic cells to induced
pluripotent stem cells (iPSCs) opens new avenues for the
aging field and has important applications for therapeutic
treatments of age-related diseases. Here we review emerging
studies on how aging and age-related pathways influence
iPSC generation and property. We discuss the exciting
possibility that reverting to a pluripotent stem cell stage erases
several deficits associated with aging and offers new strategies
for rejuvenation. Finally, we argue that reprogramming provides a
unique opportunity to model aging and perhaps exceptional
longevity.
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Introduction
Aging is associated with a dramatic increase in a wide
range of age-related diseases, including cancer, cardio-
vascular dysfunction, metabolic disorders, and neurode-
generation. Even in the absence of identifiable disease,
the physiology of organs and tissues declines throughout
life. Within a tissue, both differentiated cells and adult
stem cells are susceptible to intrinsic and extrinsic
changes during aging. For example, old cells accumulate
genomic damage and aggregated proteins, and display
telomere erosion and mitochondrial dysfunction [1–6]. In
addition to these intrinsic damages, cellular aging is also
influenced by exposure to extrinsic factors, including
inflammatory cytokines [7–9]. Despite the seemingly
irreversible nature of age-associated wear and tear, aging
is not just a one-way street toward decline. Several
examples highlight the plasticity of the aging process.
Genetic pathways (e.g. insulin-FoxO, TOR, AMPK, and
Sirtuin) as well as environmental interventions (e.g.
dietary restriction and rapamycin treatment) can delay
aging, even if initiated late in life [10–14]. Furthermore,
interventions such as parabiosis – joining the circulatory
Open access under CC BY-NC-ND license. Current Opinion in Cell Biology 2012, 24:744–756 system of an old animal to that of a young one – can
reverse some aspects of aging in somatic stem and differ-
entiated cells of the old individual, in tissues as diverse as
muscle and brain [15,16].
Reprogramming of somatic cells into cells with embryo-
nic stem cell (ESC) properties termed induced pluripo-
tent stem cells (iPSCs) is a major scientific breakthrough
for many areas of biology and medicine [17]. For the aging
field, such a discovery has several fundamental implica-
tions. First, many age-related pathologies such as neuro-
degenerative diseases could benefit from regenerative
therapies. In this way, patient-derived iPSCs hold great
promise for this type of clinical application as they bypass
issues regarding immune rejection and ethical concerns
related to human embryonic stem cell (hESC) derivation.
Second, reprogramming can be considered to mimic the
‘resetting’ that occurs during meiosis and fertilization,
which allows the formation of a new individual from two
older individuals. Thus, reprogramming may hold the key
to ‘immortality’ and provide pivotal insights into possible
rejuvenation strategies [18]. Finally, reprogramming
allows the generation of patient-specific iPSCs with
genetic predisposition to premature aging or exceptional
longevity, thereby facilitating drug screening and under-
standing of the fundamental mechanisms underlying
aging and longevity.
Many important questions stem from the interface of
aging and reprogramming. How does age of the donor
influence the generation and quality of iPSCs? Can genes
involved in aging impact the reprogramming process? Are
defects associated with cellular aging erased by repro-
gramming? Is it possible to model aging or longevity using
iPSCs? This review will highlight emerging answers to
these questions as well as remaining gaps in knowledge. A
better understanding of the influence of age on repro-
gramming may help improve the current low reprogram-
ming efficiency of somatic cells. Elucidation of the
possible erasure of age-related defects in somatic cells
by reprogramming may provide new tools to prevent or
even reverse aging in vivo.
Do aged cells reprogram as well as young
cells?
The first studies that tested how age of the donor affects
reprogramming were conducted in mice (Table 1). Com-
pared to humans, mice have the advantage of identical
genetic background and controlled environment, thereby
allowing one to focus on age as the main parameter.
These initial studies suggest that cells from older mice
tend to reprogram less efficiently than cells from youngwww.sciencedirect.com
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Table 1
Summary of the current literature on the impact of age on reprogramming. Bona fide iPSCs are defined as iPSCs expressing early and late
markers of pluripotency, in vitro and/or in vivo differentiation potential into the three germ layers
Species Cell type Protocol Age groups Reprogramming
Efficiency
Bona fide
iPSCs
Re-differentiation
potential
Reference
Mouse Dermal fibroblasts
from ear punches
(C57BL/6 mice)
OSKM 2 vs >24 months 2.2-fold higher in
younger
Not
assessed
Not assessed Li et al.,
2009 [19]
Mouse Dermal fibroblasts
(B6CBAF1 mice)
OSKM Juvenile vs
12 months
5-fold higher in
younger
Yes Haematopoietic cells
and osteoblasts
No age comparison
performed
Kim et al.,
2010 [21]
Mouse Bone marrow cells
(C57BL/6 mice)
OSKM 2 vs 23 months 5-fold higher in
younger, and
twice as fast
Yes Myeloid cells
No age comparison
performed
Cheng et al.,
2011 [22]
Mouse Muscle-derived
fibroblasts (C57BL/
6-background mdx
mice)
OSKM 1.5 vs 6 vs
14 months
6-fold higher in
1,5 and 6 months
compared to
14 months
Yes Skeletal muscle
lineages
No age comparison
performed
Wang et al.,
2011 [20]
Human Fibroblasts from
various tissues of
donors of both sexes
and with different
disease states
OSKM 8–64 years No correlation
with age
Yes Definite endoderm.
No age comparison
performed
Somers et al.,
2010 [24]
Human Dermal fibroblasts OSKM +
NANOG +
LIN28
70 years Not assessed Yes Fibroblast
No age comparison
performed
Suhr et al.,
2010 [28]
Human Dermal fibroblasts of
donors of both sexes
and with various
disease states
OSK and
OSKM
29–82 years Not assessed Yes Motor Neurons
Efficiency not
correlated to age
Boulting et al.,
2011 [25]
Human Dermal fibroblasts OSKM 84 years Not assessed Yes Neuronal lineages
No age comparison
performed
Prigione et al.,
2011 [30]
Human Senescent and
proliferative dermal
fibroblasts
OSKM +
NANOG +
LIN28
74–101 years Not assessed Yes Fibroblast
No age comparison
performed
Lapasset et al.,
2011 [26]
Human Keratinocytes OSKM 56–78 years Not assessed Yes Insulin-producing
cells
Ohmine et al.,
2012 [27]
Human Dermal fibroblasts OSKM 106–109 years Not assessed Yes Neural cells
No age comparison
performed
Yagi et al.,
2012 [29]mice [19,20,21,22]. For example, dermal fibroblasts
from old mice (>2-years) exhibit a two-fold reduction in
their ability to generate colonies that stain positive for a
stem cell marker, alkaline phosphatase (AP), compared to
fibroblasts from young adult mice (2 months-old) upon
expression of the four Yamanaka factors (Oct4, Sox2, Klf4
and c-Myc) [19]. Even more strikingly, dermal fibro-
blasts from middle-aged mice (1 year-old) were shown to
result in a five-fold lower frequency of AP+ colonies
compared to juvenile mice (exact age not stated) upon
expression of the four Yamanaka factors [21]. Further-
more, bone marrow cells from old mice (23 months-old)
generated at least five-fold fewer AP+ colonies than cells
from young adults (2 months-old), and the reprogram-
ming process was reported to take twice as long [22].
Collectively, these studies suggest an age-dependent
decline in reprogramming efficiency in mice. However,
several important points remain to be tested before such awww.sciencedirect.com general conclusion can be reached. First, most studies
only compared two age groups – old versus young, with
the young being 2 months or less. It is not yet clear
whether the observed impact of age on reprogramming is
truly a difference of aging or a difference between post-
natal development and mature adults. Furthermore,
many of the studies based their reprogramming efficiency
analysis on the number of clones that are positive for
alkaline phosphatase, an early marker of pluripotency. It
will be important to assess quantitatively other charac-
teristics of iPSCs to provide a bona fide measure of
reprogramming efficiency. Moreover, some of the studies
used only one mouse per age group. Including a larger
number of mice per age group to identify potential
variations in reprogramming efficiency will be necessary.
While there is an apparent decline in reprogramming
efficiency in aged populations of cells, it also appearsCurrent Opinion in Cell Biology 2012, 24:744–756
746 Cell differentiationthat some bona fide iPSC lines could be derived from cells
from old donors, as measured by the qualitative expres-
sion of pluripotency markers and by in vitro and in vivo
differentiation potential. Thus, aging may be a barrier for
the initiation of the reprogramming process, but once the
process is initiated, it appears to proceed in a relatively
complete manner, at least to the iPSC state. An important
remaining question is whether iPSCs derived from old
donors have the full capacity to differentiate into func-
tional cell types or whether they keep a ‘memory’ of the
initial age of the donor. Another interesting point is that
reprogramming potency seems to be impaired to a greater
extent in bone marrow cells than in dermal fibroblasts
[19,22], suggesting that different tissues may have
varying sensitivity to age-dependent changes related to
reprogramming efficiency.
Generating iPSCs from old human cells
Human studies are inherently difficult to interpret
because differences in genetic background could super-
sede the impact of age on iPSC quality. Indeed, genetic
background strongly influences reprogramming efficiency
in mice [23]. Furthermore, the conditions under which
primary fibroblasts are generated from human biopsies
and the number of passages these fibroblasts undergo
before reprogramming may also significantly impact
reprogramming efficiency. Initial studies in humans
suggest that, contrary to what has been observed in mice,
aging does not drastically impair the ability of human cells
to reprogram into bona fide iPSCs (Table 1). Somers and
colleagues generated >100 iPSC lines from fibroblasts of
12 individuals with an age-range of 8–64 years using the
four Yamanaka factors. The reprogramming efficiency
ranged from 0.1 to 1.5%, but this variation was not
significantly correlated with donor’s age. Bona fide iPSC
clones could be derived from all subjects regardless of
age, as measured by expression of pluripotency markers
and by teratoma formation assays. Furthermore, all the
iPSC lines tested could give rise to definite endoderm
cells, suggesting that age has no major impact on the re-
differentiation potential of iPSCs, at least into endoderm
[24]. However, it is important to note that in this study,
fibroblasts were obtained from different tissues, the
donors had varying forms of lung diseases, and were of
both sexes, all parameters that might have obscured a
potential impact of age on reprogramming.
Several other studies have also succeeded in deriving
bona fide iPSC lines from older patients [25,26,27,28,
29,30] (Table 1). Suhr and colleagues derived bona fide
iPSCs from primary fibroblasts of a 70-years-old patient
using a six-factors cocktail containing OCT4, SOX2,
KLF4, c-MYC, NANOG and LIN28, and succeeded in
re-differentiating them into fibroblasts. However, no
specific age comparisons were made [28]. Boulting and
colleagues compared 16 iPSC lines from seven individ-
uals of varying age (29–82 years old), sex, and healthCurrent Opinion in Cell Biology 2012, 24:744–756 status in terms of differentiation potential. There was no
correlation between donor age and the re-differentiation
efficiency of the iPSC lines. These lines expressed plur-
ipotency markers, formed the three germ layers in vitro
and in vivo and differentiated into functional motor
neurons at comparable levels [25]. Ohmine and col-
leagues derived iPSC lines from human keratinocytes
of four individuals with an age-range of 56–78 year-old,
using the four Yamanaka factors [27]. Although repro-
gramming efficiency was very low in this study
(0.0001%), bona fide iPSC lines could be derived, and
these lines expressed a range of pluripotency markers and
exhibit the ability to differentiate into the three germ
layers. Furthermore, these iPSC lines could give rise to
insulin-producing cells regardless of age [27]. Finally, two
independent studies succeeded in reprogramming cen-
tenarian human fibroblasts into iPSCs using either the
conventional four factors [29] or a six-factor cocktail
[26]. iPSC lines from centenarian fibroblasts expressed
pluripotency markers and gave rise to the three embryo-
nic lineages, showing bona fide iPSCs could be generated
from exceptionally old donors [26,29]. Thus, one com-
mon conclusion from studies in humans is that iPSCs can
be generated from old patients and these cells appear to
be able to re-differentiate in different tissues. Thus, it is
conceivable that patient-derived iPSCs could be used for
degenerative diseases, even when they originate from
older patients. However, understanding the exact impact
of age on human reprogramming will require more quan-
titative assays to accurately determine reprogramming
efficiency and re-differentiation capabilities as a function
of donor’s age. The investigation of larger numbers of
subjects with controlled genetic and environmental back-
grounds will also be needed to appropriately isolate the
age parameter. Moreover, as aging is accompanied with
accumulation of genomic mutations that may compromise
the cells’ natural defenses against tumor development
[31] (discussed below), further investigation is required to
evaluate whether iPSCs derived from old donors are more
prone to develop cancer than iPSCs derived from young
donors.
Cellular senescence, aging, and
reprogramming
Cellular senescence, which is associated with aging, may
be one of the mechanisms by which aging impairs repro-
gramming efficiency, at least in mice [19,32,33,34–
38]. Senescent cells are characterized by a virtually irre-
versible cell cycle arrest, p16INK4 induction, and hetero-
chromatin foci [39,40]. Because cell cycle progression is
believed to be a key parameter for the reprogramming
process [41,42], the cell cycle arrest due to cellular senes-
cence may represent a major barrier to reprogramming.
The number of senescent cells increases in the body
during aging [40,43,44] and in patients with genetic
diseases that recapitulate some aspects of aging such as
Hutchinson–Gilford Progeria syndrome (HGPS) [45,46]www.sciencedirect.com
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Cellular mechanisms by which age may impact reprogramming of somatic cells into iPSCs. Studies in mice indicate that aging hampers
reprogramming efficiency [19,20,21,22]. This decrease may partly be due to the fact that old tissues contain a more heterogeneous
pool of cells, including normal, pre-senescent, senescent and dysfunctional cells that may not reprogram. Senescence pathways including the
p19ARF/p53/p21CIP1 and the p16INK4/pRB pathways have been shown to constitute barriers to the reprogramming process [19,32,33,35–38]. The
reprogramming process per se induces a stress similar to senescence [33] that may push pre-senescent cells into a fully senescent state, which may
further hamper reprogramming. Although initial studies suggest that iPSCs derived from old donors are as potent as their young counterparts in terms
of pluripotency and re-differentiation potential, further studies are required to fully understand the impact of age on the iPSCs, including their
tumorigenic potential.and Dyskeratosis congenita (DC) [47]. Consequently, cell
populations obtained from old donors may contain greater
number of senescent, pre-senescent and dysfunctional
cells (Figure 1), which would decrease the reprogram-
ming efficiency. Moreover, the reprogramming process
itself appears to trigger a stress response similar to senes-
cence, called reprogramming-induced senescence (RIS)
[33]. Cells from old donors may have intrinsic senes-
cence pathways already activated (pre-senescent cells)
and may therefore be more sensitive to RIS and more
difficult to reprogram (Figure 1). Indeed, the age-de-
pendent decline in reprogramming efficiency of mouse
fibroblasts correlated with increased expression of the
Ink4/Arf locus, which contains the two anti-proliferative
genes p16INK4 and p19ARF [19]. Interestingly, the age-
dependent decline in reprogramming efficiency could be
counteracted by silencing Ink4/Arf expression using
shRNAs [19]. Consistently, knockdown of genes that
are important for cellular senescence, such as p53 and
p21CIP1, increase the efficiency of mouse and human
reprogramming by both accelerating the reprogramming
process as well as increasing the yield of iPSC colonies
[19,36–38]. These data suggest that cellular senescencewww.sciencedirect.com is at least partly responsible for the decrease in repro-
gramming associated with aging. However, senescence
does not appear to be an insurmountable barrier to
reprogramming because human senescent cells have
been successfully reprogrammed to iPSCs using a six-
factor reprogramming cocktail [26].
Aging pathways, metabolism, and
reprogramming
An intriguing question is whether interfering with aging
pathways involved in energy metabolism ameliorate the
ability of old cells (or even young ones) to generate
functional iPSCs. One of the best example of a pathway
involved in aging and metabolism is the insulin/IGF-1
pathway [13]. Deficiency in the insulin/IGF-1 receptor
extends lifespan from worms to mammals [13] and is
associated with extreme longevity in humans [48]. While
it is not yet known if genetic deficiency in the insulin/
IGF-1 pathway affects reprogramming, a recent study
showed that several chemical inhibitors of this pathway
improved reprogramming. Pharmacological inhibitor of
the insulin/IGF-1 signaling pathway, such as the inhibi-
tor of IGF1 receptor (PQ401) and a PI3K inhibitorCurrent Opinion in Cell Biology 2012, 24:744–756
748 Cell differentiation
Figure 2
Reprogramming
Metabolic switch
Somatic cell
mTOR
Insulin/
IGF-1
SIRTs
PI3K
Autophagy
AMPK
FOXOs
PQ401
LY294002
Rapamycin
PP242
Spermidine
Resveratrol
Fisetin
Metformin
A-769662
Compounds
?
iPSCs
Early phase
Escape senescence and/or facilitate
mesenchymal-to-epithelial transition
Current Opinion in Cell Biology
Compounds that modulate well-known aging and metabolism pathways affect somatic cell reprogramming [49,62]. Green boxes depict compounds
that enhance reprogramming, and red boxes depict compounds that inhibit the process. The pro-reprogramming compounds have been shown to act
in the early phase of reprogramming, potentially by preventing hyper activation of insulin/IGF-1 and mTOR pathways that may in turn induce cellular
senescence and/or facilitate mesenchymal-to-epithelial transition [49]. It is not clear yet whether treatment with metformin hampers reprogramming
or enhances it [49,62].(LY294002), increase reprogramming efficiency by 2–4
fold of mouse embryonic fibroblasts (MEFs) transduced
by retroviral vectors expressing OCT4, SOX2, KLF4 and
c-MYC [49] (Figure 2).
Another conserved protein that regulates aging is the
protein kinase mTOR. Genetic or pharmacological inhi-
bition of the mTOR pathway promotes longevity from
yeast to mammals [12,50]. mTOR regulates longevity
partly by modulating autophagy [51]. Two inhibitors of
the mTOR pathway (rapamycin and PP242) and an
inducer of autophagy (spermidine) also improved the
reprogramming efficiency of MEFs 4–5 fold (Figure 2).
The iPSC lines generated in the presence of the two
mTOR inhibitors expressed pluripotency markers, were
karyotypically normal, and could give rise to germline
chimeras [49]. It may seem counter-intuitive that inhi-
bition of two signaling pathways (insulin/IGF-1 andCurrent Opinion in Cell Biology 2012, 24:744–756 mTOR) that promote cell proliferation actually enhances
reprogramming, as proliferation is highly correlated to
reprogramming potency [41,42]. However, hyper-acti-
vation of mTOR can also induce senescence [52,53].
Inhibitors of insulin/IGF-1 and mTOR may thus act to
fine-tune the activity of these pathways to avoid cellular
senescence [54]. Accordingly, inhibition of both pathways
was shown to improve the initial phase of reprogramming
[49], a phase in which senescence acts as a major barrier
to reprogramming. In addition, these inhibitors may act
by facilitating a mesenchymal-to-epithelial transition
(MET) [49] (Figure 2), as cells of mesenchymal origin
such as fibroblast are thought to undergo MET before
they can initiate the reprogramming process into plur-
ipotent state [55,56]. Whether these inhibitors may help
the reprogramming of old cells even more than that of
MEFs is not known. It will be interesting to further
explore the molecular and cellular mechanisms by whichwww.sciencedirect.com
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in particular, whether and how autophagy is involved in
iPSC generation and function.
The AMP-dependent protein kinase (AMPK) and the
NAD+-dependent histone deacetylases of the Sirtuin
family have been implicated in promoting longevity
and metabolic health, in particular in response to some
dietary restriction regimens [57–61]. An initial study
showed that while activation of Sirtuins by two com-
pounds (Reservatrol and Fisetin) enhanced reprogram-
ming 6-fold, activation of AMPK by metformin had no
significant effect on iPSC generation [49] (Figure 2).
However, somewhat surprisingly, a second study reported
that activation of AMPK with two chemical activators
(metformin and A-769662) in fact reduced the generation
of AP+ cells from MEFs and adult human fibroblasts by
60–90% [62] (Figure 2), although it is not clear whether
these AP+ cells were indeed bona fide iPSCs. The authors
suggest that AMPK activation may prevent the metabolic
switch from oxidative to glycolytic metabolism [62], a
transition that is essential for the initiation for somatic cell
reprogramming [63–65].
Taken together, these studies suggest a functional cor-
relation between regulation of cell reprogramming and
pathways involved in aging and metabolism. This con-
nection could be harnessed for better reprogramming
efficiency and iPSC quality. These preliminary results
also raise the possibility that depending on the metabolic
state of the organism (for example, caloric restriction or
obesity), donor cells may not be more or less conducive to
reprogramming.
Epigenetic regulators of aging
Aging is accompanied with alterations in chromatin states
triggered by changes in DNA methylation, post-transla-
tional modifications of histones, and histone protein
levels. In many vertebrate species, old cells exhibit an
age-dependent global loss of DNA methylation [66,67],
an epigenetic mark generally associated with gene repres-
sion [68]. Moreover, histone marks associated with active
chromatin (e.g. H4K16ac) tend to increase with age, at
least in yeast [69]. H3K4me3 levels, which is also gener-
ally associated with active chromatin, has been shown to
change at specific genes with age in human brain [70].
Conversely, histone marks associated with repressed
chromatin (e.g. H3K27me3, H3K9me3) decrease with
age in species ranging from worms to humans [71–74].
Finally, aging is associated with a decrease in the abun-
dance of the core histone proteins H2A, H3 and H4
[69,75–79]. Thus, chromatin states appear to become less
repressed with age, which might either increase the
expression of aging genes and promote general increased
transcription/translation, thereby possibly leading to
excessive protein misfolding or increase accessibility of
DNA to damage.www.sciencedirect.com Consistent with a causative role for age-dependent
changes in chromatin states, chromatin modifiers can
influence longevity in several species. Decreasing
H4K16Ac via the Sir2 deacetylase promotes longevity
in yeast [69]. Deficiency in members of the COMPASS
complex, which is responsible for generating H3K4me3,
extends lifespan in C. elegans [80,81]. Conversely, over-
expression of RBR-2, an H3K4me3 demethylase, pro-
motes lifespan extension in C. elegans [81], and RBR-2
mutants in both C. elegans and Drosophila are short-lived
[81,82]. Depletion of UTX, an H3K27me3 demethylase,
also extends lifespan in C. elegans [71,80]. These results
suggest that manipulating chromatin states can influence
longevity, at least in invertebrates.
To the authors knowledge there are no studies to date
that have examined if the epigenetic changes of old cells
impact reprogramming efficiency or if age-dependent
epigenetic alterations are themselves affected by repro-
gramming. However, emerging evidence points to
possible antagonistic interactions between chromatin
states associated with aging and those important for
reprogramming. Several members of the H3K4me3 reg-
ulating COMPASS complex, whose deficiency extends
lifespan in worms [80,81], are upregulated during the
reprogramming process. Accordingly, knockdown of
one member of the COMPASS complex (Wdr5) in MEFs
dramatically decreases the number of AP+ and SSEA1+
clones [83]. Conversely, inhibition of histone deacety-
lases by Valproic acid or Butyrate, which leads to
increased levels of histone acetylation and chromatin
opening, improves overall reprogramming efficiency
and can even substitute for some of the reprogramming
factors [84,85]. These results suggest that chromatin
changes that are favorable for cellular reprogramming
are detrimental for organismal longevity (and vice versa).
Future investigation in this area is required to identify the
epigenetic changes of old cells and how they are impacted
by reprogramming. It would be particularly interesting to
test if the antagonistic roles of chromatin states on aging
and cellular reprogramming can be uncoupled.
Does reprogramming erase signs of age?
Reprogramming has the remarkable ability to reverse
some cellular and molecular characteristics associated
with aging, including cellular senescence, telomere ero-
sion, mitochondrial dysfunction, and global changes in
gene expression, suggesting that many of the age-associ-
ated characteristics that were once thought to be perma-
nent are, in fact, reversible (Figure 3).
Senescent cells obtained by serial passaging of dermal
fibroblasts of a 74-year-old donor could be reprogrammed
using a six-factor cocktail. iPSC lines derived from senes-
cent fibroblasts express pluripotency markers and can
give rise to the three germ layers, showing that they
are bona fide iPSCs. Interestingly, when iPSCs fromCurrent Opinion in Cell Biology 2012, 24:744–756
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Aspects of aging that can be ‘rejuvenated’ or not by reprogramming.senescent cells were re-differentiated into fibroblasts,
these fibroblasts proliferated at a similar rate as young
proliferative fibroblasts, and became senescent after a
greater number of passage doublings compared to the
donor cells [26]. Thus, cellular senescence, which is
often considered an irreversible cell cycle arrest, can be
reverted by potent reprogramming protocols.
Telomere erosion is a characteristic of aged and senescent
cells [3,86,87]. Reprogramming triggers an increase in
telomere length in cells from old mice and humans
[26,27,28,29,88,89] (Figure 3). However, whether the
resulting iPSC lines can maintain their long telomere
length over long-term passages is still subject to debate.
It was shown that iPSC lines generated from a hES-
derived cell line using a three-factor protocol (Oct4,
Sox2 and Klf4) had shorter telomeres than their parental
hESC on average. Interestingly, the iPSC lines initially
exhibited long telomeres similar to the parental cells, but
upon repeated passaging the iPSC lines lost telomere
length. The telomere shortening correlated with reduced
levels of telomerase activity in these iPSC lines,Current Opinion in Cell Biology 2012, 24:744–756 suggesting that telomere maintenance cannot be fully
restored by reprogramming. However, the authors also
observed heterogeneity in telomere dynamics between
the derived iPSC lines, where some iPSC lines were able
to maintain and even continue extending their telomeres
[89]. Similarly, it has been shown that upon re-differen-
tiation, some iPSC lines can maintain their telomeres over
extended time period, suggesting that a subpopulation of
these cells might be transformed [28,89] (Figure 3). By
contrast, iPSC lines that were generated from senescent
and centenarian human fibroblasts using a six-factor pro-
tocol exhibit maintenance of telomere length over 110
passage doublings [26]. Given the variability of telo-
mere length within iPSC lines derived from the same
donor, it will be important to test additional iPSC lines to
determine whether efficient reprogramming protocols
can trigger re-elongation of eroded telomeres to iPSCs
and progeny, without inducing cancer.
Mitochondrial properties also appear to be restored to an
ESC-like state by the reprogramming process [26,27,
30,90] (Figure 3). iPSCs from senescent and aged cellswww.sciencedirect.com
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in terms of metabolism, mitochondrial membrane poten-
tial, numbers, distribution and morphology [26]. Sim-
ilarly, a reversion of mitochondrial morphology and
functionality to ESC-like state in iPSC lines derived from
an old human subject was observed [30,90]. Transcrip-
tome analysis of iPSC lines derived from elderly patients
further confirmed a rejuvenation of mitochondria path-
ways [26,27,30]. Taken together, these studies suggest
that mitochondrial properties in aged iPSCs are restored
to a similar status to that of young iPSCs and ESCs.
Whether mitochondrial properties remain in a rejuve-
nated state upon re-differentiation is still unclear [90–
92]. It will also be interesting to test whether the age-
dependent accumulation of damaged macromolecules,
such as proteins and lipids [93] (Figure 3), and the age-
dependent changes in metabolism [94,95], are rejuve-
nated by reprogramming.
Interestingly, gene expression profiles of iPSC lines
derived from old mouse and human subjects have also
been shown to be reset to an embryonic-like state
[19,20,26,27,30] (Figure 3). Transcriptome analysis
from several groups reveals significant downregulation of
senescence/apoptosis-related genes in iPSC lines from
older individuals. These genes include p16INK4A and
p15INK4B in the p16INK4A/RB pathway and p21CIP1 in
p19ARF/p53 pathway, as well as proapoptotic genes such
as FAS, CASP8, CASP7, BAD and TP53AIP1 [19,27].
Comparison of the gene expression profiles of prolifera-
tive and senescent fibroblasts derived from a 74-year-old
patient, the corresponding six-factor cocktail-induced
iPSC lines, and publicly available gene expression data-
sets of hESC and iPSC lines derived by four-factors
revealed that the aged fibroblasts have an ‘aging signa-
ture’ regardless of their proliferation status, and that a six-
factor protocol resets this aging signature more efficiently
than a four-factor protocol. Furthermore, the transcrip-
tome of a fibroblast re-differentiated from the prolifera-
tive and senescent fibroblasts of the 74-year-old patient
and a centenarian clustered better with fibroblasts
derived from hESCs than the parental cells, indicating
a ‘rejuvenation’ of the transcriptome [26]. Collectively,
these studies suggest that the transcriptome of old cells is
‘rejuvenated’ by the reprogramming process. However,
the gene expression profiles of the iPSCs are not identical
to hESCs, and although the re-differentiated fibroblasts
clustered better with young fibroblasts than with their
parental cells, they are still distinguishable from the
young fibroblasts. Thus, these differences in the tran-
scriptome between re-differentiated ‘rejuvenated’ fibro-
blasts and young fibroblasts may be reminiscence of
old age.
One tantalizing aspect of reprogramming-induced reju-
venation that has not been investigated thoroughly is the
epigenetic status of iPSCs derived from old donorswww.sciencedirect.com (Figure 3). Epigenetic changes to the chromatin are
now widely accepted as part of organismal aging, in
particular alterations in DNA methylation  status [96–
101]. Recent evidence suggests that iPSCs from mouse
and human retain an epigenetic memory, namely DNA
methylation signatures, of their tissue of origin, and that
this impacts their differentiation potential [21,102–
105]. Interestingly, this epigenetic memory does not
necessarily manifest itself at the pluripotency stage –
iPSCs derived from different tissues were shown to
exhibit proper morphology, express pluripotency mar-
kers, and were able to differentiate into the three
embryonic layers in vitro and in vivo. Instead, this epi-
genetic memory may manifest later, during re-differen-
tiation into specific cell types that require the specific loci
that have residual epigenetic marks [21,102,105]. As of
yet, no studies have directly characterized old cells in
regard to their epigenetic state before and after repro-
gramming. It would be interesting to investigate whether
iPSCs derived from aged cells retain a memory of their
age, in the form of DNA methylation or histone modi-
fications, and whether this memory affects their differ-
entiation potential. Interestingly, a recent study shows
that reprogramming of cancer cells into a pluripotent
state makes the tumor cells less aggressive in vivo. The
authors observed that the reprogramming process led to a
major re-structuring of the epigenome, resetting the
epigenetic status of oncogenes from an active into a
bivalent or inactive state [106]. This suggests that the
reprogramming process per se is able to affect the epi-
genome of aberrant cells.
Aspects of aging that cannot be reset by
reprogramming
Many aspects of aging are resettable by reprogramming,
which opens avenues for novel therapeutic interventions
of age-related symptoms and diseases. However, the
accumulation of nuclear and mitochondrial DNA damage
that is associated with aging [31] is likely to be an aspect
of aging that cannot be reversed by reprogramming
(Figure 3). This accumulated genomic damage may
represent a safety issue when mutations occur in import-
ant cellular maintenance genes such as p53, rendering the
cells more prone to tumor development. Indeed, several
studies have shown that p53 deficiency in MEFs give rise
to iPSCs with increased chromosomal instability, persist-
ent damaged DNA, and malignant tumor-forming poten-
tial [32,107]. Accordingly, several studies reported
genetic aberrations in iPSC lines derived from old indi-
viduals [25,30]. However, genomic abnormalities have
also been shown to occur during the reprogramming
process, while maintaining the iPSCs in culture and upon
re-differentiation [108–111]. Therefore, further investi-
gation is required to clarify whether these genetic aberra-
tions are truly an age-dependent risk or whether they are
due to the reprogramming process or the protocols used
(or a combination of all three). In addition, the iPSC linesCurrent Opinion in Cell Biology 2012, 24:744–756
752 Cell differentiationthat were derived from old donors and that carried kar-
yotypic abnormalities were as susceptible to drug-
induced apoptosis as their young counterparts. The
authors interpreted this result as an indication that iPSCs
from aged donors are not predisposed to cancer [30]. It
will be interesting to compare mice derived from iPSCs
originating from young and old donors to determine if
tumorigenesis is positively correlated to donor’s age.
iPSCs from individuals with premature aging
or exceptional longevity
Hutchinson–Gilford Progeria syndrome (HGPS) is a rare
genetic disease in which children show several signs of
premature aging, including increased risk of cardiovas-
cular diseases and hair loss [45,46]. The disease is caused
by a mutation in the lamin A (LMNA) gene, which leads
to the production of a truncated and toxic version of the
lamin A protein termed progerin. Cells from HGPS
patients display abnormal nuclear morphology, loss
of heterochromatin markers H3K9me3, HP1a and
HDAC1, and increased DNA damage [74,112]. Two
recent studies showed that it is possible to derive iPSCs
from fibroblasts of HGPS patients [113,114]. HGPS-
derived iPSC lines expressed pluripotency markers,
formed the three germ layers in vitro and in vivo, and
were able to re-differentiate into a variety of different
cell-types. Upon reprogramming, HGPS-derived iPSC
lines no longer expressed progerin (similar to ESCs).
Interestingly, the nuclear defects and epigenetic altera-
tions associated with the disease were reverted back to
normal, confirming that the reprogramming process is
able to restore several defects associated with premature
aging syndromes as well as physiological aging. How-
ever, upon differentiation, HGPS-derived iPSC lines
start to re-express the deleterious form of Lamin A,
and as a consequence, these cells exhibit signs of pre-
mature senescence  such as reduced telomere length
even at early passages [113,114]. The premature
senescence of progeny of HGPS-derived iPSCs is
particularly evident in mesenchymal stem cells (MSCs)
and vascular smooth muscle cells (VSMCs). MSCs
generated from HGPS-derived iPSCs are more sensitive
to hypoxic conditions [114]. As MSCs are normally
found in low O2 niches in vivo, this observation raises the
possibility that MSC exhaustion underlies HGPS path-
ology [114]. Furthermore, VSMCs generated from
HGPS-derived iPSCs are more sensitive to a number
of stress stimuli (e.g. electrical stimulation) that these
cells normally endure in vivo [114], which could
explain the specific vulnerability of VSMCs in HGPS
patients. These studies are examples of how disease
modeling of premature aging syndromes by iPSCs can
give novel insights into the pathology of aging. It will be
interesting to use relevant HPSG-derived cells (in
particular MSCs and VSMCs) as models for chemical
or genetic screens to identify ways to alleviate age-
related characteristics.Current Opinion in Cell Biology 2012, 24:744–756 On the other end of the age spectrum are individuals with
exceptional longevity, such as centenarians and super-
centenarians (110 years old or more). In these individuals,
longevity is known to be largely due to genetic factors. It
will be interesting to determine if iPSC lines derived from
these individuals exhibit specific qualities compared to
cells from individuals with normal lifespan, and whether
some lineages are more affected than others. Centenar-
ian-derived iPSC lines could also serve as cellular models
to understand the molecular mechanisms of exceptional
longevity.
Concluding remarks
The past few years have seen significant advances in
understanding the relationship between aging and repro-
gramming. While it is now clear that cells from old
patients can be reprogrammed, more studies will be
needed to better understand how age impacts iPSC
generation and quality. Larger numbers of individuals,
additional age groups, and fewer confounds will be critical
to isolate the age parameter from other components. As
there is significant variation among iPSC lines derived
from the same individual, it will also be important to
characterize several iPSC lines from the same individual.
Such systematic studies will be particularly essential for
human iPSCs, given the heterogeneous genetic back-
ground and uncontrolled environment of humans, two
factors that impact organismal longevity and presumably
affect reprogramming.
It will also be important to investigate the combined
impact of age and tissue of origin on iPSC generation
and quality. There is emerging evidence that tissue from
different niches may exhibit differing sensitivity to age-
dependent decline in reprogramming properties [19,20,
22]. Such differences in how age impacts iPSC depend-
ing on the tissue of origin would be particularly important
from a clinical standpoint, as some sources of cells
for iPSC derivation could be detrimental for stem cell
therapies.
Characterizing the epigenetic state of old cells before and
after reprogramming and differentiation will be a key step
in identifying the age-dependent epigenetic changes that
are reversible and those that remain as a ‘memory’ of the
aged state. Such a knowledge may open new avenues for
mimicking rejuvenation at the molecular level and may
also provide ways of improving the reprogramming effi-
ciency and iPSC quality.
Could one derive iPSC lines from an older patient,
generate specific committed progenitors, and use these
cells to alleviate aging or age-related disease in the same
patient? Several hurdles might need to be overcome to
use aged patient-derived iPSCs for stem cell therapies.
One potential issue may be that even though reprogram-
ming erases most molecular signs of aging, iPSCs derivedwww.sciencedirect.com
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instability and neoplastic risk due to unrepaired damage.
Thus, more iPSC lines might need to be screened, and
their genome sequenced to ensure that key tumor sup-
pressor or oncogenic pathways are not affected. Another
key hurdle will be whether the reimplantation of the cells
in the old environment of the patient will turn the clock
forward in an accelerated manner and ‘re-age’ the cells.
This is a particularly important problem, given the
systemic impact of an aged environment on stem cell
function in several tissues, including muscle and brain
[8,9].
Despite hurdles for the clinical use of iPSC cells, the
process of reprogramming has opened many new avenues
for the field of aging. iPSC lines could be used to model
the genetic basis of aging and longevity, thereby allowing
the screening and identification of novel factors that
improve premature aging or affect exceptional longevity.
In the likely event that not all signs of aging are reverted
by reprogramming, iPSCs from old vs young individuals
would also provide a model for aging in the tissue culture
dish. Finally and importantly, the rejuvenation of many
age-related characteristics by reprogramming also pro-
vides an opportunity for the field to understand the basis
of ‘immortality’.
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